Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | PTGES | O14684 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29717105 | 1.00 | MAOB (0.63) | MAOBLMNAHPGDMCL1MAOA | |
| SCHEMBL629952 | 0.90 | MAOB (0.74) | MAOBLMNAHPGDMCL1MAOA | |
| SCHEMBL7947250 | 0.87 | TDP1 (0.65) | MAOBLMNAMCL1MAOAPTGES | |
| SCHEMBL5336493 | 0.87 | MAOB (0.61) | MAOBLMNAHPGDMCL1MAOA | |
| SCHEMBL10468397 | 0.86 | MEN1 (0.63) | MAOBLMNAMCL1MAOACA12 | |
| Methyl 2,4-Dihydroxybenzoate SCHEMBL5199862 | 0.86 | MAOB (0.68) | MAOBLMNAHPGDMCL1MAOA | |
| SCHEMBL22692220 | 0.86 | MAOB (0.59) | MAOBLMNAHPGDMCL1NPC1 | |
| SCHEMBL22873361 | 0.86 | MAOB (0.59) | MAOBLMNAHPGDMCL1NPC1 | |
| SCHEMBL11563262 | 0.86 | MAOB (0.56) | MAOBLMNAHPGDNPC1RAB9A | |
| SCHEMBL31580963 | 0.85 | MAOB (0.77) | MAOBLMNAMAOAPTGESNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2023-11-30 | — | — | US | disclosed |
| CN-116367832-A | Substituted heteroaryl compounds and uses thereof | 苏州华明道康生物医药有限公司 | 2023-06-30 | — | — | CN | disclosed |
| EP-4085056-A1 | POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER | Berg LLC (US) | 2022-11-09 | — | — | EP | disclosed |
| CN-115210229-A | Polycyclic amides as UBE2K modulators for the treatment of cancer | 博格有限责任公司 | 2022-10-18 | — | — | CN | disclosed |
| WO-2022078294-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2022-01-06 | — | — | US | disclosed |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2022-01-06 | — | — | US | disclosed |
| US-11091447-B2 | UBE2K modulators and methods for their use | BERG LLC (US) | 2021-08-17 | — | — | US | disclosed |
| WO-1998037056-A1 | PHENOXYPROPANOLAMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 1998-08-27 | — | — | WO | disclosed |
| CN-1159797-A | Aryloxy and arylthiopropanolamine derivative suseful as beta 3-adrenoreceptor agonists and antagonists of the beta 1 and beta 2-adrenoreceptors and pharmaceutical composition thereof | SMITHKLINE BEECHAM PLC (GB) | 1997-09-17 | — | — | CN | disclosed |
| EP-0772585-A1 | ARYLOXY AND ARYLTHIOPROPANOLAMINE DERIVATIVES USEFUL AS BETA 3-ADRENORECEPTOR AGONISTS AND ANTAGONISTS OF THE BETA 1 AND BETA 2-ADRENORECEPTORS AND PHARMACEUTICAL COMPOSITION THEREOF | SMITHKLINE BEECHAM PLC (GB) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996004234-A1 | ARYLOXY ANDARYCTHIO PROPANOLAMINE DERIVATIVES USEFUL AS B3-ADRENORECEPTOR AGONISTS AND ANTAGONS OF THE B1 AND B2 ADRENORECEPTORS AND PHARMACEUTICAL COMPOSITION THEREOF | SMITHKLINE BEECHAM PLC (GB) | 1996-02-15 | — | — | WO | disclosed |
| WO-1996004233-A1 | ARYLOXY AND ARYLTHIOPROPANOLAMINE DERIVATIVES USEFUL AS BETA 3-ADRENORECEPTOR AGONISTS AND ANTAGONISTS OF THE BETA 1 AND BETA 2-ADRENORECEPTORS AND PHARMACEUTICAL COMPOSITION THEREOF | SMITHKLINE BEECHAM PLC (GB) | 1996-02-15 | — | — | WO | disclosed |
| US-5350748-A | 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion | WARNER-LAMBERT COMPANY (US) | 1994-09-27 | — | — | US | disclosed |
| EP-0003084-B1 | SPIROBENZOFURANONE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICINES | Takeda Chemical Industries, Ltd. (JP) | 1982-02-24 | — | — | EP | disclosed |
| US-4284644-A | Spirobenzofuranone compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1981-08-18 | — | — | US | disclosed |
| EP-0003084-A1 | Spirobenzofuranone compounds, processes for their preparation and their use as medicines | Takeda Chemical Industries, Ltd. (JP) | 1979-07-25 | — | — | EP | disclosed |
| US-4146631-A | ANTIALLERGENS, RESPIRATORY DISORDERS | MAY & BAKER LIMITED (GB) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091447-B2 | UBE2K modulators and methods for their use | UBE2N, UBE2B, UBE2E1 | MAOB 2363/4885LMNA 3530/4885HPGD 1216/4885 |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | MAOB 2363/4885LMNA 3530/4885HPGD 1216/4885 |
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | SSB, BTK, PADI6 | MAOB 122/4885LMNA 3065/4885HPGD 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.